61644-18-6

Basic information

• Product Name: Chloromethyl isobutyrate
• Synonyms: Chloromethyl isobutyrate;(Isobutyryloxy)methyl chloride;Chloromethyl 2-methylpropanoate;Chloromethyl 2-methylpropionate;Propanoicacid, 2-methyl-, chloromethyl ester
• CAS NO: 61644-18-6
• Molecular Formula: C₅H₉ClO₂
• Molecular Weight: 136.58
• EINECS: -0
• Mol File: 61644-18-6.mol

Chemical Properties

• Boiling Point: 124.604 °C at 760 mmHg
• Flash Point: 33.736 °C
• Appearance: /
• Density: 1.081 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Sparingly), Methanol (Slightly)
• CAS DataBase Reference: Chloromethyl isobutyrate(CAS DataBase Reference)
• NIST Chemistry Reference: Chloromethyl isobutyrate(61644-18-6)
• EPA Substance Registry System: Chloromethyl isobutyrate(61644-18-6)

Safety Data

• Hazardous Substances Data: 61644-18-6(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
Chloromethyl isobutyrate is used as a chemical intermediate for the production of various organic compounds, contributing to the synthesis of a wide range of chemical products.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, chloromethyl isobutyrate is used as a raw material in the manufacturing process, playing a crucial role in the development of medicinal compounds.
Used in Agricultural Product Production:
Chloromethyl isobutyrate is also utilized in the production of agricultural products, where it may contribute to the formulation of agrochemicals or other related substances.
Used as a Solvent in Chemical Reactions:
Due to its solvent properties, chloromethyl isobutyrate is employed in various chemical reactions to facilitate processes and improve the efficiency of synthesis.
Safety Precautions:
Given its hazardous nature, chloromethyl isobutyrate should be handled with care to minimize the risk of skin, eye, and respiratory irritation. It is essential to avoid contact with oxidizing agents and to manage its flammability to ensure safe usage in industrial applications.

Upstream product

• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 79-30-1 isobutyryl chloride 
• 49715-04-0 chlorosulfuric acid chloromethyl ester 
• 79-31-2 isobutyric Acid 
• 50-00-0 formaldehyd 
• 19455-20-0 potassium isobutyrate 
• 74-97-5 chlorobromomethane 

Downstream Products

• 442682-38-4 bis[(isobutyryloxy)methyl] 4-[2-(difluoromethoxy)phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate 
• 400884-07-3 3-[(isobutyryloxy)methyl] 5-(2-propoxyethyl) 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate 
• 400884-08-4 3-[(isobutyryloxy)methyl] 5-methyl 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate 
• 143417-85-0 4-Chloro-2-[(furan-2-ylmethyl)-amino]-5-sulfamoyl-benzoic acid isobutyryloxymethyl ester 
• 87589-31-9 4-(tert-Butoxycarbonylamino-methyl)-cyclohexanecarboxylic acid isobutyryloxymethyl ester 

Relevant articles and documents

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE

The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.

COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY

The present invention relates to compound of Formula I or a pharmaceutically acceptable salt thereof (Formula I) wherein R1 is Formula (AA) or Formula (BB) where the squiggly line indicates the point of attachment to the rest of the molecule; R2 is F or Formula (CC) where the squiggly line indicates the point of attachment to the rest of the molecule; R3 is H or CH3; Z is O or is absent; and R4 is -OC1-3alkyl, C1-30alkyl, or -N(CH3)2.

NMDA ANTAGONIST PRODRUGS

Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.

Substituted aza indole compounds and salts thereof, composition and use thereof

The invention provides a substituted azaindole compound having a structure as represented by a formula (I) and a pharmaceutically acceptable salt and a medicinal preparation thereof. The compound is used for adjusting activity of protein kinase and adjusting intercellular or intracellular signal response. The invention further relates to a pharmaceutical composition including the compound and a method of applying the pharmaceutical composition to treatment of highly proliferative diseases of mammals, especially of mankind.

NMDA ANTAGONIST PRODRUGS

Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.

SUBSTITUTED AZAINDOLE COMPOUNDS, SALTS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE

The present invention provides substituted azaindole prodrugs, methods of making said prodrugs, pharmaceutical compositions of said prodrugs and methods of using said prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer.

NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES

Novel compounds and their synthesis are described. Methods for using these compounds in the prevention or treatment of cancer, a bacterial infection or a viral infection in a subject are also described.

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS

A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.

SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS

The present invention relates to the synthesis and application of novel chiral/ achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.